Form 8-K - Current report:
SEC Accession No. 0001140361-25-000292
Filing Date
2025-01-06
Accepted
2025-01-06 07:05:30
Documents
15
Period of Report
2024-12-31
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20041130_8k.htm   iXBRL 8-K 36077
2 EXHIBIT 99.1 ef20041130_ex99-1.htm EX-99.1 6728
6 image0.jpg GRAPHIC 41317
  Complete submission text file 0001140361-25-000292.txt   241988

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA gyre-20241231.xsd EX-101.SCH 4025
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE gyre-20241231_lab.xml EX-101.LAB 21967
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gyre-20241231_pre.xml EX-101.PRE 16073
18 EXTRACTED XBRL INSTANCE DOCUMENT ef20041130_8k_htm.xml XML 4205
Mailing Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130 (619) 949-3681
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

EIN.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51173 | Film No.: 25509020
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)